Company Overview and News

349
Will AT&T/Time Warner Ruling Accelerate M&A?

12h seekingalpha
The market’s positive reaction to the AT&T/Time Warner decision paves the way for other vertical deals.
FB S AMCX DBS CMCSA TWX AAPL NFLX CI TWC AET

107
Here's Why You Should Hold on to Hartford Financial Stock

17h zacks
The insurance industry is well-poised for growth on a gradually stabilizing operating environment, Fed rate hikes and benefits of the tax overhaul. Taking these factors into consideration, it will be a prudent move to consider The Hartford Financial Services Group, Inc. (HIG - Free Report) stock seems a profitable stock to hold on to, given its underlying strength and good growth prospects. The company’s Zacks Consensus Estimate for current-year earnings has been revised 5.
BRK.A HD HIG HGH NMIH HCJ AET Y HCI HCIIP HIG.WS

139
Healthcare Industries Are About To Experience An Entire Transformation

2018-06-14 seekingalpha
Healthcare and all its many sectors including insurance are about to see a massive campaign to attack the exorbitant cost of healthcare in this country.
AMZN NYTAB AET

92
Trade of the Day: AmerisourceBergen Corporation (ABC)

2018-06-14 investorplace
To receive further updates on this AmerisourceBergen Corporation (NYSE:ABC) trade as well as an alert when it’s time to take profits, sign up for a risk-free trial of SlingShot Trader today.
ABC T TWX CVS TWC AET

248
With or Without Time Warner, AT&T Stock Isn't Worth Buying | InvestorPlace

2018-06-13 investorplace
The acquisition of Time Warner Inc (NYSE:TWX) by AT&T Inc. (NYSE:T) appears to be a go. And the approval of the AT&T-TWX merger, announced Tuesday afternoon, already is reverberating through the market.
DISCB DISCA CCV TWX CCZ DISCK AMCX VIAB AET CMCSK DIS DISC CBS VIA FOX TMUSP CBS.A TMUS CMCSA TWC CBS.WD S T CCV.CL CPV FOXA ESRX

333
AT&T-TWX Deal Approval to Spark M&A Frenzy: 4 ETFs to Profit

2018-06-13 zacks
After a six-week trial, U.S. District Court Judge Richard Leon approved AT&T’s (T - Free Report) $85.4 billion purchase of Time Warner (TWX - Free Report) without any condition. This will give the pay-TV provider an ownership of cable channels such as HBO and CNN as well as film studio Warner Bros. AT&T vowed to close the deal by Jun 20. This long-awaited decision will change the landscape of the media industry by setting the stage for mergers of media companies and telecom providers.
CBS DISH CBS.A CCV CMCSA TWX NFLX CCZ TWC CBS.WD CHTR S AMZN VIAB CCV.CL CPV AET CMCSK DIS

170
Why The Huge AT&T Win May Bode Well For Other Takeover Targets

2018-06-13 247wallst
If you were a betting man or woman, you may have lost a bunch betting on the merger chances for AT&T Inc. (NYSE: T) and Time Warner Inc. (NYSE: TWX). It surely seemed that the clear consensus on Wall Street for the past few months was that the deal would not get approved, especially when the Trump administration had voiced their disapproval. But just like the Las Vegas hockey team getting to the Stanley Cup Finals, it’s never over until it’s over.
FOX TMUS TWX CVS TWC S T AVGO CI BRCM QCOM AET FOXA ESRX

62
AT&T (T) Sinks, Time Warner (TWX) Gains as Federal Judge Approves Merger

2018-06-12 zacks
A federal judge has approved AT&T’s (T - Free Report) $85 billion merger with Time Warner (TWX - Free Report) , handing the telecom giant a massive victory in what has been the most intense antitrust case in decades.
GOOGL TWX NFLX UTX TWC AET

143
AT&T, Justice Department await decision that could determine future of media

2018-06-12 channelnewsasia
AT&T Inc , which owns DirecTV, awaits a court ruling on Tuesday that will determine if it can buy Time Warner Inc , a decision that could prompt a cascade of pay TV companies buying television and movie makers and the first big test of the Trump administration's antitrust teams.
FOX CCV.CL CCV CMCSA TWX CCZ CI CVS TWC FOXA AET CMCSK

146
AT&T, Justice Department await decision that could determine future of media

2018-06-12 reuters
WASHINGTON (Reuters) - AT&T Inc, which owns DirecTV, awaits a court ruling on Tuesday that will determine if it can buy Time Warner Inc, a decision that could prompt a cascade of pay TV companies buying television and movie makers and the first big test of the Trump administration’s antitrust teams.
FOX CCV.CL CCV CMCSA TWX CCZ CI CVS TWC FOXA AET CMCSK

49
Aetna: If The Deal Falls Through

2018-06-12 seekingalpha
Seeking Alpha contributor DoctoRx recently made a case for buying both Aetna and CVS, but he also warned Aetna could plummet if the deal falls through.
AET

69
KKR will buy Envision Healthcare for $5.57 billion plus debt

2018-06-12 livemint
New York: Private equity firm KKR & Co. will buy Envision Healthcare Corp. for $5.57 billion plus debt, after a lengthy sale process by the hospital staffing and surgical center company.
CG CVS AET UNH TMH

153
Cigna-Express Scripts: Analysis Of Each Stock And Of The Deal

2018-06-11 seekingalpha
The closely followed ESRX has agreed to be bought out by CI, which has a similar market cap after ESRX rose post-deal and CI fell.
BRK.A CI ANTM CVS HUM AET

50
The Case To Own Both Aetna And CVS Health

2018-06-11 seekingalpha
I like the odds that the deal goes through, and I like AET as a new money buy around $181.
CVS AET

49
Great Expectations

2018-06-11 seekingalpha
The expected rate of return on an investment portfolio is an key factor in investment and retirement planning for the individual investor.
DUKH DUK AET

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to AET / Aetna, Inc. on message board site Silicon Investor.

Aeterna Zentaris (AEZS) AEterna Zentaris (NASDAQ: AEZS)
Aethlon Medical BSEQ Aetna, Inc. (AET)
AETC: Applied Extrusion Tech. Aeterna (M.AEL)
Aetna ( aet) AETG - American Entertainment Group - Up on Volume
Advanced Encryption Technology (AETI) Goes Public w/a Bang AETI announces acquisition of Metisse Information Systems
CUSIP: 00817Y108